Treatment with Docetaxel and Enzalutamide for ductal adenocarcinoma of the prostate in elderly patients:a case report and literature review / 中华老年医学杂志

ABSTRACT

Objective To summarize the clinical features of prostatic ductal adenocarcinoma and to explore its therapeutic approaches.Methods A case report on an elderly patient with prostatic ductal adenocarcinoma who received endocrine therapy,chemotherapy,radiotherapy,and Enzalutamide therapy after prostate biopsy in November 2013.We summarized and analyzed the patient's clinical manifestations and reviewed relevant literature.Results The patient showed a low sensitivity to Docetaxel;the PSA level of the patient was over 30 times lower than the baseline level after monotherapy with Enzalutamide;bilateral pulmonary nodules and mediastinal lymph nodes reduced in size;a bone scan showed no significant change in bone metastases.At present,there is no report on treatment for prostatic ductal adenocarcinoma with Enzalutamide.Conclusions Enzalutamide therapy is effective and safe for prostate ductal adenocarcinoma and should be encouraged in clinical practice.Studies with larger sample sizes and longer follow-ups are needed in the future.